Figure 1.

Risk of cardiorenal events in patients treated with liraglutide (upper panel) or semaglutide (lower panel) vs placebo, by diabetes duration at baseline. LEADER total population: 9340. LEADER total population with diabetes duration available: 9321. SUSTAIN 6 total population (all patients with diabetes duration available): 3297. MACE comprised CV death, nonfatal MI and nonfatal stroke. Expanded MACE comprised MACE components plus coronary revascularization and hospitalization for unstable angina or heart failure. Nephropathy events were defined as new onset of macroalbuminuria or doubling of serum creatinine level and eGFR ≤45 mL/min/1.73 m², the need for continuous renal‐replacement therapy or death from renal disease. Abbreviations: CI, confidence interval; CV, cardiovascular; eGFR, estimated glomerular filtration rate; GLP‐1, glucagon‐like peptide‐1; MACE, major adverse cardiovascular events; N, number of patients with event; R, events per 100 patient years of observation